A clinical formulation indicated for Pain Relief. Specific mechanism supports the management of chronic systemic inflammation to aid in reducing physical discomfort.
Designed to manage multiple myeloma and severe skin symptoms of leprosy by addressing immune response and targeting abnormal cell growth in adult patients.
Mechanism of Action
Thalidomide suppresses the immune system and reduces inflammation by inhibiting TNF-alpha. In cancer, it blocks the formation of new blood vessels that tumors need to grow and stimulates immune cells to attack malignant cells.
Route of Administration
Oral
Onset Time
Variable; 1–3 months for cancer
Duration
24 hours
Contraindications
Pregnancy, Women of childbearing potential (unless strict REMS), Known hypersensitivity
Severe Adverse Events
Severe birth defects (phocomelia), Venous thromboembolism, Deep vein thrombosis, Severe skin reactions (TEN), Cardiac rhythm issues
Information for Thalix is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
